AmeritoxSM, the nation's leader in pain medication monitoring, in conjunction with Beth Israel Medical Center, this week announced the results of a new study showing that the company's reference database tool, Rx Guardian CDSM, based on urine drug monitoring results from a large database of adherent oxycodone-prescribed patients, generalized well to a geographically and demographically distinct group of patients.
Study findings were presented today at PAINWeek®, the national conference on pain for frontline practitioners, the nation's largest pain conference.
Satisfied Users & 
Approved Press Releases
